TPDB06217

Evidence 1 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 3.1 µg/mL

Target

Target Organism B. subtilis ATCC 6633

Source & Reference

Database Source dbAMP

Other

Source Activity Label	Source Definition
Antibacterial	dbAMP classified as Antibacterial under the Anti-bacterial function class.

Evidence Text

active against Gram+ B. subtilis ATCC 6633 (MIC 3.1 ug/ml), M. luteus ATCC 10240 (MIC 3.1 ug/ml), S. aureus ATCC 6538p (MIC 6.3 ug/ml), S. epidermid

Evidence 2 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 3.1 µg/mL

Target

Target Organism M. luteus ATCC 10240

Source & Reference

Database Source dbAMP

Other

Evidence Text

active against Gram+ B. subtilis ATCC 6633 (MIC 3.1 ug/ml), M. luteus ATCC 10240 (MIC 3.1 ug/ml), S. aureus ATCC 6538p (MIC 6.3 ug/ml), S. epidermidis ATCC 12228 (MIC 6.3 ug/ml), Gram- E

Evidence 3 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 6.3 µg/mL

Target

Target Organism Staphylococcus aureus ATCC 6538p

Source & Reference

Database Source dbAMP

Other

Evidence Text

gainst Gram+ B. subtilis ATCC 6633 (MIC 3.1 ug/ml), M. luteus ATCC 10240 (MIC 3.1 ug/ml), S. aureus ATCC 6538p (MIC 6.3 ug/ml), S. epidermidis ATCC 12228 (MIC 6.3 ug/ml), Gram- E. coli ATCC 25922 (MIC 12.5 ug/ml), S.

Evidence 4 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 6.3 µg/mL

Target

Target Organism Staphylococcus epidermidis ATCC 12228

Source & Reference

Database Source dbAMP

Other

Evidence Text

C 3.1 ug/ml), M. luteus ATCC 10240 (MIC 3.1 ug/ml), S. aureus ATCC 6538p (MIC 6.3 ug/ml), S. epidermidis ATCC 12228 (MIC 6.3 ug/ml), Gram- E. coli ATCC 25922 (MIC 12.5 ug/ml), S. dysentariae ATCC 9752 (MIC 25 ug/ml), S. t

Evidence 5 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 12.5 µg/mL

Target

Target Organism Escherichia coli ATCC 25922

Source & Reference

Database Source dbAMP

Other

Evidence Text

), S. aureus ATCC 6538p (MIC 6.3 ug/ml), S. epidermidis ATCC 12228 (MIC 6.3 ug/ml), Gram- E. coli ATCC 25922 (MIC 12.5 ug/ml), S. dysentariae ATCC 9752 (MIC 25 ug/ml), S. typhimorium ATCC 14028 (MIC 50 ug/ml), K. pn

Evidence 6 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 25 µg/mL

Target

Target Organism S. dysentariae ATCC 9752

Source & Reference

Database Source dbAMP

Other

Evidence Text

l), S. epidermidis ATCC 12228 (MIC 6.3 ug/ml), Gram- E. coli ATCC 25922 (MIC 12.5 ug/ml), S. dysentariae ATCC 9752 (MIC 25 ug/ml), S. typhimorium ATCC 14028 (MIC 50 ug/ml), K. pneumonia ATCC 10031 (MIC 12.5 ug/ml), and

Evidence 7 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 50 µg/mL

Target

Target Organism S. typhimorium ATCC 14028

Source & Reference

Database Source dbAMP

Other

Evidence Text

/ml), Gram- E. coli ATCC 25922 (MIC 12.5 ug/ml), S. dysentariae ATCC 9752 (MIC 25 ug/ml), S. typhimorium ATCC 14028 (MIC 50 ug/ml), K. pneumonia ATCC 10031 (MIC 12.5 ug/ml), and P. aeruginosa ATCC 27853) (MIC 12.5 ug/ml)

Evidence 8 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 12.5 µg/mL

Target

Target Organism K. pneumonia ATCC 10031

Source & Reference

Database Source dbAMP

Other

Evidence Text

g/ml), S. dysentariae ATCC 9752 (MIC 25 ug/ml), S. typhimorium ATCC 14028 (MIC 50 ug/ml), K. pneumonia ATCC 10031 (MIC 12.5 ug/ml), and P. aeruginosa ATCC 27853) (MIC 12.5 ug/ml).

Evidence 9 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 22.25 mM

Detail Source Activity Anticancer

Activity Measurement 22.25 mM

Target

Cancer Type Skin Cancer

Cell Line SK-MEL-2

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents US_008076284_B2

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 10 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 14.53 mM

Detail Source Activity Anticancer

Activity Measurement 14.53 mM

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents US_008076284_B2

Evidence 11 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 12.55 mM

Detail Source Activity Anticancer

Activity Measurement 12.55 mM

Target

Cancer Type Ovarian Cancer

Cell Line SK-OV-3

Tissue Affected Ovary

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents US_008076284_B2

Evidence 12 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 22.51 mM

Detail Source Activity Anticancer

Activity Measurement 22.51 mM

Target

Cancer Type Gastric Cancer

Cell Line MKN-45

Tissue Affected Stomach

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents US_008076284_B2

Evidence 13 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 29.1 mM

Detail Source Activity Anticancer

Activity Measurement 29.1 mM

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents US_008076284_B2

Evidence 14 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 21.48 mM

Detail Source Activity Anticancer

Activity Measurement 21.48 mM

Target

Cancer Type Renal Cancer

Cell Line A-498

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents US_008076284_B2

Evidence 15 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 14.8 mM

Detail Source Activity Anticancer

Activity Measurement 14.8 mM

Target

Cancer Type Colon Cancer

Cell Line HCTl-16

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents US_008076284_B2

Evidence 16 Activity

Activity

Activity Raw

Not Available

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line NCI-H630

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents US_008076284_B2

Evidence 17 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 21.48 mM

Detail Source Activity Anticancer

Activity Measurement 21.48 mM

Target

Cancer Type Renal Cancer

Cell Line A-498

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents WO_2007133033_A1

Evidence 18 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 14.53 mM

Detail Source Activity Anticancer

Activity Measurement 14.53 mM

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents WO_2007133033_A1

Evidence 19 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 14.8 mM

Detail Source Activity Anticancer

Activity Measurement 14.8 mM

Target

Cancer Type Colon Cancer

Cell Line HCTl-16

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents WO_2007133033_A1

Evidence 20 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 22.51 mM

Detail Source Activity Anticancer

Activity Measurement 22.51 mM

Target

Cancer Type Gastric Cancer

Cell Line MKN-45

Tissue Affected Stomach

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents WO_2007133033_A1

Evidence 21 Activity

Activity

Activity Raw

Not Available

Detail Source Activity Anticancer

Target

Cancer Type Colon Cancer

Cell Line NCI-H630

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents WO_2007133033_A1

Evidence 22 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 29.1 mM

Detail Source Activity Anticancer

Activity Measurement 29.1 mM

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents WO_2007133033_A1

Evidence 23 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 22.25 mM

Detail Source Activity Anticancer

Activity Measurement 22.25 mM

Target

Cancer Type Skin Cancer

Cell Line SK-MEL-2

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents WO_2007133033_A1

Evidence 24 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 12.55 mM

Detail Source Activity Anticancer

Activity Measurement 12.55 mM

Target

Cancer Type Ovarian Cancer

Cell Line SK-OV-3

Tissue Affected Ovary

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2011

Patents WO_2007133033_A1

Evidence 25 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 24.76 µM

Detail Source Activity Anticancer

Activity Measurement 24.76 µM

Target

Cancer Type Ovarian Cancer

Cell Line SK-OV-3

Tissue Affected Ovary

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 26 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 21.48 µM

Detail Source Activity Anticancer

Activity Measurement 21.48 µM

Target

Cancer Type Renal Cancer

Cell Line A-498

Tissue Affected Renal

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 27 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 14.53 µM

Detail Source Activity Anticancer

Activity Measurement 14.53 µM

Target

Cancer Type Lung Cancer

Cell Line A-549

Tissue Affected Lung

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 28 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 14.8 µM

Detail Source Activity Anticancer

Activity Measurement 14.8 µM

Target

Cancer Type Colon Cancer

Cell Line HCT-116

Tissue Affected Colon

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 29 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 22.51 µM

Detail Source Activity Anticancer

Activity Measurement 22.51 µM

Target

Cancer Type Gastric Cancer

Cell Line MKN-45

Tissue Affected Stomach

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 30 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 29.10 µM

Detail Source Activity Anticancer

Activity Measurement 29.10 µM

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 31 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 22.25 µM

Detail Source Activity Anticancer

Activity Measurement 22.25 µM

Target

Cancer Type Skin Cancer

Cell Line SK-MEL-2

Tissue Affected Skin

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 32 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50= 12.55 µM

Detail Source Activity Anticancer

Activity Measurement 12.55 µM

Target

Cancer Type Ovarian Cancer

Cell Line SK-OV-3

Tissue Affected Ovary

Assay & Model

Assay MTT/MTS assay

Testing Time 72-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2012

Evidence 33 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 3.1 µg/mL

Target

Target Organism B. subtilis ATCC 6633

Source & Reference

Database Source dbAMP

Other

Source Activity Label	Source Definition
Antifungal	dbAMP classified under the Anti-fungal function class.

Evidence Text

active against Gram+ B. subtilis ATCC 6633 (MIC 3.1 ug/ml), M. luteus ATCC 10240 (MIC 3.1 ug/ml), S. aureus ATCC 6538p (MIC 6.3 ug/ml), S. epidermid

Evidence 34 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 3.1 µg/mL

Target

Target Organism M. luteus ATCC 10240

Source & Reference

Database Source dbAMP

Other

Evidence Text

active against Gram+ B. subtilis ATCC 6633 (MIC 3.1 ug/ml), M. luteus ATCC 10240 (MIC 3.1 ug/ml), S. aureus ATCC 6538p (MIC 6.3 ug/ml), S. epidermidis ATCC 12228 (MIC 6.3 ug/ml), Gram- E

Evidence 35 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 6.3 µg/mL

Target

Target Organism Staphylococcus aureus ATCC 6538p

Source & Reference

Database Source dbAMP

Other

Evidence Text

gainst Gram+ B. subtilis ATCC 6633 (MIC 3.1 ug/ml), M. luteus ATCC 10240 (MIC 3.1 ug/ml), S. aureus ATCC 6538p (MIC 6.3 ug/ml), S. epidermidis ATCC 12228 (MIC 6.3 ug/ml), Gram- E. coli ATCC 25922 (MIC 12.5 ug/ml), S.

Evidence 36 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 6.3 µg/mL

Target

Target Organism Staphylococcus epidermidis ATCC 12228

Source & Reference

Database Source dbAMP

Other

Evidence Text

C 3.1 ug/ml), M. luteus ATCC 10240 (MIC 3.1 ug/ml), S. aureus ATCC 6538p (MIC 6.3 ug/ml), S. epidermidis ATCC 12228 (MIC 6.3 ug/ml), Gram- E. coli ATCC 25922 (MIC 12.5 ug/ml), S. dysentariae ATCC 9752 (MIC 25 ug/ml), S. t

Evidence 37 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 12.5 µg/mL

Target

Target Organism Escherichia coli ATCC 25922

Source & Reference

Database Source dbAMP

Other

Evidence Text

), S. aureus ATCC 6538p (MIC 6.3 ug/ml), S. epidermidis ATCC 12228 (MIC 6.3 ug/ml), Gram- E. coli ATCC 25922 (MIC 12.5 ug/ml), S. dysentariae ATCC 9752 (MIC 25 ug/ml), S. typhimorium ATCC 14028 (MIC 50 ug/ml), K. pn

Evidence 38 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 25 µg/mL

Target

Target Organism S. dysentariae ATCC 9752

Source & Reference

Database Source dbAMP

Other

Evidence Text

l), S. epidermidis ATCC 12228 (MIC 6.3 ug/ml), Gram- E. coli ATCC 25922 (MIC 12.5 ug/ml), S. dysentariae ATCC 9752 (MIC 25 ug/ml), S. typhimorium ATCC 14028 (MIC 50 ug/ml), K. pneumonia ATCC 10031 (MIC 12.5 ug/ml), and

Evidence 39 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 50 µg/mL

Target

Target Organism S. typhimorium ATCC 14028

Source & Reference

Database Source dbAMP

Other

Evidence Text

/ml), Gram- E. coli ATCC 25922 (MIC 12.5 ug/ml), S. dysentariae ATCC 9752 (MIC 25 ug/ml), S. typhimorium ATCC 14028 (MIC 50 ug/ml), K. pneumonia ATCC 10031 (MIC 12.5 ug/ml), and P. aeruginosa ATCC 27853) (MIC 12.5 ug/ml)

Evidence 40 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 12.5 µg/mL

Target

Target Organism K. pneumonia ATCC 10031

Source & Reference

Database Source dbAMP

Other

Evidence Text

g/ml), S. dysentariae ATCC 9752 (MIC 25 ug/ml), S. typhimorium ATCC 14028 (MIC 50 ug/ml), K. pneumonia ATCC 10031 (MIC 12.5 ug/ml), and P. aeruginosa ATCC 27853) (MIC 12.5 ug/ml).

Evidence 41 Activity

Activity

Activity Endpoint 5% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 6.3 µg/mL

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

5% Hemolysis | 6.3 | µg/mL | target cell: Human erythrocytes

Target

Target Cell Human erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Activity optimization of an undecapeptide analogue derived from a frog-skin antimicrobial peptide | Mol Cells | 2011

Evidence 42 Hemolysis

Source & Reference

source HemoPI PD_Hemolysis

Database Source PD_Hemolysis